UBS issued a sell recommendation on Oscar Health (OSCR) shares, citing market pressure and expected revenue slumps due to ACA/Obamacare.
1 report, 1 independent
Updated Jul 18
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
UBS issued a sell recommendation on Oscar Health (OSCR) shares, citing market pressure and expected revenue slumps due to ACA/Obamacare.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
UBS
Swiss multinational investment bank and financial services company
-
Oscar Health
U.S. health insurance company
Nothing else this week.
Related events
- UBS is investing in the Southern California market and has appointed new Market Directors in San Diego as part of its expansion.
- UBS initiated coverage with a 'buy' rating for Persimmon plc.
- UBS maintains a Buy rating on Snowflake stock amid competition from Databricks and Microsoft.
- UBS analyst maintained a Buy rating on Applied Materials stock.
- Wholesale Club filed a disclosure document with the SEC, coinciding with UBS increasing its price target.
Coverage
Newest first; wire copies grouped- Insider MonkeyOscar Health (OSCR) Falters on UBS’ “Sell” Reco We recently published These 10 Stocks Just Lost Their Spark. Oscar Health, Inc. (NYSE:OSCR) is one of the worst-performing companies on Thursday. Oscar